Hyogo College of Medicine is a private university in Nishinomiya, Hyōgo, Japan, established in 1972 by Shigeki Morimura.

During the past decade, Hyogo College of Medicine conducted 39 clinical trials. In the 10-year time frame, 39 clinical trials started and 12 clinical trials were completed, i.e. on average, 30.8% percent of trials that started reached the finish line to date. In the past 5 years, 15 clinical trials started and 9 clinical trials were completed. i.e. 60% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Hyogo College of Medicine" #1 sponsor was "Eli Lilly and Company" with 7 trials, followed by "Hyogo Medical University" with 6 trials sponsored, "Shire" with 5 trials sponsored, "Hoffmann-La Roche" with 2 trials sponsored and "Takeda" with 2 trials sponsored. Other sponsors include 25 different institutions and companies that sponsored additional 33 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hyogo College of Medicine" #1 collaborator was "Japan Clinical Oncology Group" with 2 trials as a collaborator, "Tokyo Medical and Dental University" with 2 trials as a collaborator, "Abbott Medical Devices" with 1 trials as a collaborator, "Asahi Intech" with 1 trials as a collaborator and "Daiichi Sankyo Co., Ltd." with 1 trials as a collaborator. Other collaborators include 16 different institutions and companies that were collaborators in the rest 26 trials.

According to Clinical.Site data, the most researched conditions in "Hyogo College of Medicine" are "Crohn's Disease" (5 trials), "Ischemic Stroke" (5 trials), "Ulcerative Colitis" (5 trials), "Colorectal Cancer" (3 trials) and "Breast Cancer" (2 trials). Many other conditions were trialed in "Hyogo College of Medicine" in a lesser frequency.

Most popular intervention types in "Hyogo College of Medicine" are "Drug" (34 trials), "Procedure" (11 trials), "Device" (8 trials), "Other" (7 trials) and "Biological" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (11 trials), "Ontamalimab" (4 trials), "Mirikizumab" (3 trials), "Lasmiditan" (2 trials) and "UFT adjuvant chemotherapy" (2 trials). Other intervention names were less common.

The vast majority of trials in "Hyogo College of Medicine" are 51 trials for "All" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Hyogo College of Medicine". 1 are not yet recruiting, 11 are recruiting, 6 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 22 completed trials in Hyogo College of Medicine, undefined suspended trials, and 6 terminated clinical trials to date.

Out of the total trials that were conducted in Hyogo College of Medicine, 0 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 26 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 12 trials that are defined as “Not Applicable".